1. Home
  2. CUE vs STIM Comparison

CUE vs STIM Comparison

Compare CUE & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • STIM
  • Stock Information
  • Founded
  • CUE 2014
  • STIM 2003
  • Country
  • CUE United States
  • STIM United States
  • Employees
  • CUE N/A
  • STIM N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • STIM Medical/Dental Instruments
  • Sector
  • CUE Health Care
  • STIM Health Care
  • Exchange
  • CUE Nasdaq
  • STIM Nasdaq
  • Market Cap
  • CUE 77.3M
  • STIM 83.5M
  • IPO Year
  • CUE 2018
  • STIM 2018
  • Fundamental
  • Price
  • CUE $1.31
  • STIM $2.46
  • Analyst Decision
  • CUE Strong Buy
  • STIM Buy
  • Analyst Count
  • CUE 5
  • STIM 4
  • Target Price
  • CUE $5.00
  • STIM $4.67
  • AVG Volume (30 Days)
  • CUE 406.9K
  • STIM 896.9K
  • Earning Date
  • CUE 03-10-2025
  • STIM 03-04-2025
  • Dividend Yield
  • CUE N/A
  • STIM N/A
  • EPS Growth
  • CUE N/A
  • STIM N/A
  • EPS
  • CUE N/A
  • STIM N/A
  • Revenue
  • CUE $9,532,000.00
  • STIM $72,711,000.00
  • Revenue This Year
  • CUE $73.11
  • STIM $1.97
  • Revenue Next Year
  • CUE $11.02
  • STIM $7.96
  • P/E Ratio
  • CUE N/A
  • STIM N/A
  • Revenue Growth
  • CUE 149.53
  • STIM 5.03
  • 52 Week Low
  • CUE $0.45
  • STIM $0.52
  • 52 Week High
  • CUE $2.93
  • STIM $5.07
  • Technical
  • Relative Strength Index (RSI)
  • CUE 52.47
  • STIM 75.35
  • Support Level
  • CUE $1.21
  • STIM $1.40
  • Resistance Level
  • CUE $1.75
  • STIM $2.80
  • Average True Range (ATR)
  • CUE 0.18
  • STIM 0.28
  • MACD
  • CUE 0.00
  • STIM 0.08
  • Stochastic Oscillator
  • CUE 45.00
  • STIM 77.18

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Share on Social Networks: